title: Data acquisition for the histoculture drug response assay in lung cancer.
abstract: OBJECTIVE
  Application of the histoculture drug response assay for lung cancer was investigated by using data acquired from lung cancer specimens.
  
  
  METHODS
  From May 1994 through February 2005, histoculture drug response assay data were obtained from 359 lung cancer specimens held in our institute. We examined chemosensitivities of the tissues to cisplatin, doxorubicin, mitomycin C, 5-fluorouracil, docetaxel, paclitaxel, etoposide, irinotecan, and gemcitabine. Cutoff inhibition rates were determined with each drug for non-small cell lung cancer and were used to calculate predictabilities for chemotherapy responses.
  
  
  RESULTS
  The evaluability of the histoculture drug response assay was high at 97.4%. Good predictability, including true-positive and true-negative rates of 73.2% and 100%, respectively, with an accuracy of 83.0%, was observed.
  
  
  CONCLUSIONS
  The histoculture drug response assay appears to be applicable to non-small cell lung cancer for the prediction of responses to chemotherapy.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan. yositatu@mail.wakayama-med.ac.jp
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yoshimasu
authors.forename: Shoji
authors.initials: S
authors.lastname: Oura
authors.forename: Issei
authors.initials: I
authors.lastname: Hirai
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tamaki
authors.forename: Yozo
authors.initials: Y
authors.lastname: Kokawa
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Hata
authors.forename: Fuminori
authors.initials: F
authors.lastname: Ohta
authors.forename: Rie
authors.initials: R
authors.lastname: Nakamura
authors.forename: Mitsumasa
authors.initials: M
authors.lastname: Kawago
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Tanino
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Okamura
authors.forename: Tomoko
authors.initials: T
authors.lastname: Furukawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001707:Biopsy, Needle; D002945:Cisplatin / Q000494:pharmacology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D005047:Etoposide / Q000494:pharmacology; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000494:pharmacology; D011336:Probability; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D014407:Tumor Cells, Cultured; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D005047:Etoposide; D004317:Doxorubicin; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil; D000093542:Gemcitabine